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After a large outbreak of Legionnaires’ disease in the Netherlands, we determined risk factors for intensive
care unit (ICU) admission and death and the impact of adequate therapy on ICU-free survival among 141
hospitalized patients. Overall mortality rate was 13%, and ICU mortality rate was 36%. Smoking, tempera-
ture >38.5°C, and bilateral infiltrates shown on chest x-ray were independent risk factors for ICU admis-
sion or death (all p<0.05). Starting adequate therapy within 24 hours after admission resulted in a higher
ICU-free survival rate compared to therapy initiation after 24 hours: 78% versus 54%, respectively
(p=0.005).  However, delay in providing therapy to patients with urinary antigen tests with negative results
did not influence outcome. These data suggest that by using the urinary antigen test on admission a more
tailored approach to patients with community-acquired pneumonia may be applied.
evere Legionnaires’ disease has an overall mortality rate of
10% to 30% (1–3), and 30% to 50% of patients require
admission to an intensive care unit (ICU) (1,4). One of the
most important determinants of outcome is the early initiation
of adequate therapy after admission (1,5).  Administering
appropriate antibiotics for Legionella pneumophila during the
empiric treatment of patients with community acquired pneu-
monia has been advocated (6). Given the low frequency of
Legionnaires’ disease, this strategy is costly and leads to over-
consumption of antibiotics. Therefore, many physicians have
not adopted these guidelines in daily practice. Identifying
those patients with community-acquired pneumonia caused by
L. pneumophila is difficult.
In March 1999 one of the largest outbreaks of Legion-
naires’ disease since the first described outbreak in Philadel-
phia (7) occurred in the Netherlands. The outbreak originated
at the Westfriesian Flora, an annual flower show combined
with a consumer products exhibition, held February 19–Febru-
ary 28, 1999. The flower show was visited by 77,061 persons,
and Legionnaires’ disease developed in at least 188 (8). The
size of the outbreak provided a unique opportunity to deter-
mine which clinical factors on hospital admission predict ICU
admission or death (ICU/death). We also evaluated whether
the rapid urinary antigen test can help identify those patients
with Legionnaires’ disease for whom adequate therapy cannot
be delayed.
Patients and Methods
Study Group
On March 12, 1999, the Dutch population was alerted by
newspapers and a special broadcast that a flower show was
identified as probable origin of an outbreak of Legionnaires’
disease (9). To collect clinical data, we obtained written
informed consent from patients with Legionnaires’ disease
who had visited the flower show or their relatives. The study
was approved by the medical ethical committee of the Aca-
demic Medical Center in Amsterdam. 
The following definitions were used to categorize the
patients:“confirmed Legionnaires’ disease” was defined as the
presence of a new infiltrate shown on the chest x-ray on
admission and one or more of the following laboratory criteria:
1) isolation of L. pneumophila from a respiratory sample (28
patients), 2) detection of L. pneumophila serogroup 1 antigen
in a urine sample (Binax Now Legionella urinary antigen test;
Binax, Portland, ME) (86 patients), 3) seroconversion to posi-
tive immunoglobulin (Ig)G or IgM (or both) antibody levels to
L. pneumophila, or a fourfold rise in antibody titers to L. pneu-
mophila in paired acute-phase and convalescent-phase sera (62
patients). Antibodies to L. pneumophila were determined by
using a commercial enzyme linked immunosorbent assay (IgM
cutoff >140 U/mL and IgG cutoff > 70 U/mL, serogroup 1–7;
Serion, Institut Virion-serion GmbH, Wurzburg, Germany) or
a microagglutination antibody assay (IgM, serogroup 1-12;
Regional Laboratory of Public Health, Tilburg, the Nether-
lands). In three patients, a commercial enzyme immunoassay
(Binax EIA, Binax; Biotest EIA, Biotest AG, Dreiech, Ger-
many) was positive in concentrated urine, while other diagnos-
tic tests were negative.
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“Probable Legionnaires’ disease” was defined as the pres-
ence of a new infiltrate shown on the chest x-ray on admission
and either a single high antibody titer (microagglutination
assay 1:>256; 2 patients) or a positive polymerase chain reac-
tion analysis of sputum (1 patient) (10). Patients who visited
the flower show and in whom radiologically confirmed pneu-
monia developed within 4 weeks were also considered to have
probable Legionnaires’ disease when no other cause of the
pneumonia could be established (18 patients). Patients were
excluded if the first symptoms occurred more than 4 weeks
after they visited the flower show. None of the patients were
hospitalized during the month preceding admission. 
Data Collection and Definitions
Data on the following variables were collected from the
medical chart (if data were missing, patients were interviewed
by telephone): ,1) Premorbid conditions: age, sex, smoking >1
cigarette per day), alcohol intake (>2 units per day), use of
immunosuppressive medication (ongoing treatment with che-
motherapy or steroids >10 mg/day), underlying diseases such
as chronic obstructive pulmonary disease, diabetes mellitus,
chronic renal insufficiency, cancer (solid or hematologic neo-
plasm), and chronic cardiac disease (considered present if car-
diac medication was used at the time of the flower show visit).
2) Day of visiting the flower show, first day of illness, and date
of admission  3) Symptoms and results of physical examination
on admission. 4) Routine biochemical and hematologic labora-
tory tests obtained on admission. 4) Urinary antigen test results
collected from the microbiologic laboratory that performed the
test. The overall agreement between the Binax NOW and the
enzyme immunoassay Binax EIA (Binax Legionella Urinary
Antigen EIA Kit: Binax) has been found to be 98% (11). 6)
Chest radiograph results on admission and 48–72 hours later
reviewed by attending hospital radiologist. Radiographic pro-
gression during this period was defined as an increase in den-
sity or size of infiltrate, or progression to multiple lobes. 7)
Antibiotic treatment. Adequate therapy was considered a mac-
rolide or a fluoroquinolone, with or without rifampicin. 8)
Admission to the ICU, death, and renal insufficiency. 
At the time of the patient’s admission, Legionnaires’ dis-
ease was defined as severe when two or more of the following
conditions were present: 1) respiratory rate >30 breaths /
minute, 2) chest radiograph showing bilateral involvement or
involvement of multiple lobes, 3) shock (systolic blood pres-
sure below 90 mmHg or diastolic blood pressure below 60
mmHg), 4) PaO2 <60 mmHg or arterial oxygen saturation
<92%. For assessment of severity, we used the minor criteria
for severity of community-acquired pneumonia described by
the American Thoracic Society (12) since the major criteria
are indicators for ICU admission by themselves. 
Statistical Analysis
The independent relation between clinical factors and the
dependent variable, ICU admission or death (whatever came
first), were assessed with univariate and multivariate logistic-
regression models. Factors with a p value >0.20 in the multi-
variate analysis were excluded from the final multivariate
analysis. Continuous variables were compared using a t test
for groups; categorical variables were compared by using the
chi-square test. A two-tailed p value of 0.05 or less was con-
sidered to indicate statistical significance. 
Kaplan Meier survival analysis was used to compare the
ICU-free survival between patients in whom adequate therapy
was initiated within or later than 24 hours after admission.
ICU-free survival was defined as survival without admission
to the ICU during hospitalization. 
Results
Patients
Of 188 identified patients with confirmed or probable
Legionnaires’ disease during the outbreak (8), 161 patients
gave permission to collect clinical data (Figure 1). Since
severity of illness did not warrant hospital admission in 20
patients and limited clinical, laboratory and radiologic infor-
mation was available for these 20 patients, they were not
included in the final analysis. Among these 20 patients were
15 confirmed and 5 probable cases; none of these patients died
during the course of Legionnaires’ disease. The final analysis
was done on 141 hospitalized patients.
Forty-two (30%) of these 141 patients were admitted to the
ICU, 40 (95%) of whom had confirmed Legionnaires’ disease.
Figure 1. Patient disposition and selection. ICU, intensive care unit.RESEARCH
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Overall mortality rate was 13%, and ICU mortality rate was
36% (Figure 1). The median incubation time was 7 days
(range 1–18 days). The incubation time did not significantly
differ between patients with severe Legionnaires’ disease
(mean 6.8 days, [SD 3.5]) and those with nonsevere pneumo-
nia (mean 7.8 days [SD 3.1]: t test p=0.13) or between patients
who were admitted to the ICU or died (mean 7.0 days, [SD
3.1]) and those who did not (mean 7.7 days, [SD 3.5]: t test
p=0.26). 
The nationwide alert on March 12 led to an increase in
hospital admissions. Patients admitted after the alert (n=71)
were less severely ill: 21% had severe Legionnaires’disease in
contrast to 44% before the alert (n=70). As expected, patients
with severe Legionnaires’ disease (46/141, 33%) had an
increased risk for ICU admission or death compared with non-
severely ill patients (OR 4.5, CI 2.1 to 9.6), p=0.001). 
Characteristics on Admission
The patients’ clinical, laboratory, and radiologic data on
admission are shown in Table 1. The median age was 67 years
(range 21–92 years) and more were male (58%). Eighty-eight
(62%) patients had at least one underlying disease; cardiac dis-
ease was the most common. In the univariate analysis, smok-
ing, dyspnea, fever above 38.5°C, plasma creatinine level
>100 mmol/L, and bilateral infiltrates or pleural effusions
shown on the chest x-ray at admission were found to predict
subsequent ICU admission or death (Table 1). In the multivari-
ate analysis, smoking, temperature >38.5°C, and bilateral infil-
trates on admission were independent risk factors for ICU
admission or death (Table 2).
During hospitalization, lung infiltrates shown on the chest
x-ray progressed within 24–48 hours in 40% of the patients.
This progression was not associated with ICU admission or
death. In 39 patients (35%), renal insufficiency developed dur-
ing admission (serum creatinine level above 130 mmol/L at
any time during admission). Development of renal insuffi-
ciency was associated with ICU admission or death (OR 5.4,
CI 2.3 to 12.7). None of the patients who survived had persis-
tent renal insufficiency. In this large group of patients with
Legionnaires’ disease, no other symptoms suggested extrapul-
monary foci of infection.
Therapy and Delay in Therapy
Of the 70 patients admitted before the nationwide alert on
March 12, 44 (63%) were treated with adequate antibiotics with
a median delay of 1.5 days (range 0–14 days). After the alert,
antibiotics were changed to a macrolide or a fluoroquinolone
for 21 patients, and 5 patients were never treated with adequate
antibiotics (three of them died). All patients admitted after the
alert received adequate therapy within a median of 0 days
(range 0–3 days). Next, we studied the influence of immediate
start of adequate treatment compared with delayed treatment on
the outcome. Initiation of adequate therapy within 24 hours
after admission resulted in a higher ICU-free survival rate com-
pared with initiation after 24 hours: 78% versus 54% (Figure 2;
Table 1. Univariate analysis of factors determining outcomea
No. patients 
(%)
Odds ratio 
(95% CI)b
p value
Patient characteristics
Male 82 (58) 1.5 (0.7 to 3.1) 0.30
Age >67 years 75 (53) 1.0 (0.5 to 2.1) 0.98
Underlying diseases
COPD 11 (8) 0.8 (0.2 to 3.1) 0.73
Diabetes mellitus 16 (11) 1.0 (0.3 to 3.0) 0.95
Renal insufficiency 3 (2) 1.1 (0.1 to 12.1) 0.96
Cardiac disease 48 (34) 1.0 (0.5 to 2.0) 0.90
Cancer 10 (7) 0.5 (0.1 to 2.5) 0.41
Immunosuppressive medicationd 11 (8) 1.9 (0.5 to 6.5) 0.52
Smokingc 65 (48) 2.4 (1.2 to 5.1) 0.02
Alcohol intakec 26 (59) 3.7 (0.8 to 15.8) 0.08
Symptoms
Fever 119 (84) 0.8 (0.3 to 2.0) 0.63
Myalgia 31 (22) 0.6 (0.2 to 1.4) 0.21
Headache 36 (26) 0.6 (0.3 to 1.5) 0.30
Cough 97 (69) 1.0 (0.5 to 2.2) 0.99
Dyspnea 79 (56) 2.6 (1.2 to 5.5) 0.01
Diarrhea 25 (18) 1.3 (0.5 to 3.1) 0.63
Confusion 31 (22) 1.8 (0.8 to 4.0) 0.18
Physical examination
Temperature >38.5°C 101 (72) 3.6 (1.4 to 9.3) 0.009
Respiratory rate >18/minc 34   (85) 5.6 (0.6 to 53.4) 0
Biochemistryc
Sodium <130 mmol/L 36 (26) 2.1 (1.1 to 4.7) 0.06
Creatinine >100 µmol/L 73 (52) 2.1 (1.0 to 4.4) 0.05
CPK >200 U/L 25 (50) 1.4 (0.5 to 4.2) 0.57
ASAT >100 U/L 21 (18) 1.7 (0.6 to 4.4) 0.30
γ -GT >100 U/L 12 (13) 0.42 
(0.09 to 2.03)
0.28
PO2  <9.7 kPa 96 (83) 0.64 
(0.24 to 1.70)
0.37
X-ray results
Bilateral infiltratese 38 (27) 3.5 (1.6 to 7.6) 0.002
Pleural effusion 15 (11) 3.8 (1.2 to 11.3) 0.002
Progression within 48 hrsc,f 46 (41) 1.6 (0.7 to 3.4) 0.25
aLogistic regression analysis. 
bCI: confidence interval, COPD, chronic obstructive pulmonary disease, CPK, creati-
nine phosphokinase; ASAT, aspartate aminotransferase; g-GT, gamma glutamyltrans-
ferase.
cData for smoking (>1 cigarette per day), alcohol intake (>2 U per day), breathing fre-
quencies, laboratory tests, and progression of infiltrates were available for a proportion 
of patients. Cutoff levels for CPK, ASAT, and α -GT are two times the upper normal 
limit. 
dImmunosuppressive medication is defined as ongoing treatment with chemotherapy or 
steroids >10 mg/day. 
eUnilateral infiltrate was the reference group.
f Radiographic progression during 24–48 hours was defined as an increase in density or 
size of the infiltrate, or progression to multiple lobes.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1451
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log rank: p= 0.005). The difference in ICU-free survival was
not explained by differences in severity of pneumonia in the
two groups, since the percentage of patients with severe pneu-
monia in the group treated within 24 hours (31% severe
Legionnaires’ disease) did not significantly differ from the per-
centage in the group adequately treated after 24 hours (36%
severe Legionnaires’ disease; chi square: p=0.5).
A Binax Now urinary antigen test with positive results can
provide a diagnosis of Legionella pneumonia within 1 hour.
This test was positive in 86/141 (61%), negative in 51/141
(36%) and not done in 4/141 (3%) of the patients. Table 3
shows the results of other diagnostic tests of patients with pos-
itive and negative urinary antigen test results. In 16 patients
with negative urinary antigen test results, no other test had
positive results, although the clinical and epidemiologic fea-
tures strongly suggested Legionnaires’ disease. Two of these
patients were admitted to the ICU. Patients with negative uri-
nary antigen test results had a higher ICU-free survival rate
than patients with positive test results: 90% ICU-free survival
compared with 58% of those with positive test results (Figure
3A; log rank: p=0.0001). No effect on outcome was found
when initiation of adequate therapy was delayed in patients
with a negative urinary antigen test (Figure 3B, 92% vs. 84%
ICU-free survival; log rank: p= 0.46). In contrast, patients with
positive urinary antigen test results in whom adequate therapy
was started within 24 hours after admission had a higher ICU-
free survival rate compared with patients in whom therapy was
initiated after 24 hours (67% vs. 48% , Figure 3C; log rank: p=
0.09), resulting in a relative risk reduction of 38%. The pro-
portion of patients with severe pneumonia was comparable for
both groups of patients with a positive urinary antigen test
(within 24 hours: 39%, after 24 hours, 45% severe Legion-
naires’ disease, chi square: p= 0.58).
In addition, 36 (38%) of 95 patients with nonsevere
Legionnaires’ disease were treated with adequate antibiotic
therapy >24 hours after admission; 13 of those patients (36%)
had a poor outcome. In 10 (77%) of these patients, the urinary
antigen test was positive for L. pneumophila, indicating that
these patients should have been identified as high risk on
admission.
Discussion
Since the first outbreak of Legionnaires’ disease in Phila-
delphia in 1976 (7), several outbreaks have been described that
were linked to hospitals, hotels, cooling-towers, and whirlpool
baths (13–16). The outbreak reported here is the largest out-
break associated with a contaminated whirlpool spa located at
the exhibition hall of a flower exhibition. Analysis of 141 hos-
pitalized patients showed that a history of smoking, fever
>38.5°C, and bilateral infiltrates shown on chest x-ray were
associated with an increased risk for ICU admission or death.
A urinary antigen test with positive results was also associated
with poor outcome. Initiation of adequate therapy within 24
hours after admission showed a higher ICU-free survival rate
compared to initiation of therapy after 24 hours. No protective
effect of early adequate therapy was found in patients with
Legionnaires’ disease and a urinary antigen test negative for L.
Table 2. Multivariate analysis of factors determining outcome
Prognostic factora
Odds ratio (95% CI)b 
(n=141) p value
Smoking 2.5 (1.1 to 5.6) 0.03
Dyspnea at presentation 2.1 (0.9 to 4.8) 0.09
Temperature >38.5°C 2.9 (1.0 to 8.6) 0.05
Plasma creatinine >100 µmol/L 2.0 (0.9 to 4.6) 0.11
Bilateral infiltrates 4.2 (1.7 to 10.3) 0.002
Pleural effusion 3.4 (0.99 to 11.6) 0.053
aPrognostic factors with p< 0.05 in the univariate analysis were entered. Factors with p 
value >0.2 in the multivariate analysis were excluded.
bCI, confidence interval.
Figure 2. Kaplan-Meier curve for intensive care unit (ICU)–free survival.
ICU-free survival for patients treated with adequate antibiotics within
and >24 h after admission.:___ adequate antibiotic therapy started
within 24 h after admission (n=85); ----- adequate antibiotic therapy
started >24 h after admission (n=56).
Table 3. Positive results of other diagnostic tests of patients with 
positive and negative urinary antigen testsa
Diagnostic test
Positive urinary 
antigen test (n=86)
Negative urinary 
antigen test (n=51)
Sputum culture 23 3
Fourfold rise in titer/
seroconversion
35 27
Polymerase chain reaction 9 1
Single high titer 5 3
Positive urinary antigen ELISAb 
test in concentrated urinec
NA 7
No positive test results 29 17
aUrinary antigen test results were based on the test result of the qualitative immuno-
chromatographic assay (Binax Now, Binax, Portland, ME). 
bELISA, enzyme-linked immunosorbent assay; NA, not applicable.
cPositive Binax EIA and Biotest EIA in concentrated urine samples.RESEARCH
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pneumophila. However, in patients with positive urinary test
results, early adequate therapy reduced the risk of ICU admis-
sion and death by 38%. 
The endpoint of either ICU admission or death was chosen
because only 18 patients died, which strongly decreased the
power of the analysis. In clinical practice, preventing ICU
admission with all the disadvantages of such an admission in
terms of sickness and death, is one of the goals of early treat-
ment. Since >80% of the diseased patients were first admitted
to the ICU, we chose to combine ICU admission and death as a
composite primary outcome parameter.
We analyzed 141 hospitalized patients and excluded 20
outpatients. However, this group represents only 20 out of 161
patients, and the described 141 patients represent 88% of all
patients. In a study by Boshuizen et al. (17), a survey among
the 700 exhibitors at the flower show revealed no symptomatic
infections (for example, Pontiac fever); these researachers
concluded that either pneumonia develops in exposed persons
or they remain healthy. Therefore, this study elucidates the
complete range of the severity of the pneumonia that develops
in these patients. 
The case definition for probable cases was broad enough to
ensure inclusion of patients who died before the diagnostic
work-up for Legionella was completed. Of the 21 probable
case-patients, 18 had no single diagnostic test with positive
results and showed no evidence of infection by other microor-
ganisms (4 ICU admissions of which 2 died). Despite clinical
and epidemiologic features suggestive of Legionnaires’ dis-
ease, other undetected causes of pneumonia cannot be
excluded. 
Patients with Legionnaires’ disease are more likely to have
severe pneumonia requiring ICU admission than are patients
with community-acquired pneumonia caused by other organ-
isms (1,18,19). In this study, 42 (30%) patients) were admitted
to the ICU. The overall mortality rate (13%) and ICU mortal-
ity rate (36%) in our patients were consistent with earlier
reports (1,3,4).
For all patients, the exposure day and the date when first
symptoms occurred were known. The incubation time ranged
from 1 to 18 days, which is longer than the upper limit of 12
days reported previously (7,20). The virulence of the causative
Legionella strain, as assessed by its potential for intracellular
growth (21), did not differ from that of other clinical isolates
and cannot account for this long incubation time. This longer
incubation means that Legionnaires’ disease can no longer be
excluded as a potential cause of community-acquired pneumo-
nia when, for example, the person traveled >12 days ago.
Male gender, older age, underlying diseases like chronic
obstructive pulmonary disease, diabetes mellitus, and immun-
osuppressive medication, reported by others as predictors for
fatal outcome (2–4), were not associated with poor outcome in
this study, although the prevalence of underlying diseases in
our population was similar to the prevalence in earlier studies
describing community-acquired Legionnaires’ disease. This
difference from other studies might be explained by the fact
that in our study no selection was made for ICU patients, and
no patients with nosocomial disease were included (2–4,22).
Patients who sought treatment with bilateral infiltrates
(27%) and with pleural effusion (11%) had an increased risk
for ICU admission or death. In a prospective study on chest
radiographic findings in patients with community-acquired
Legionnaires’ disease, 16% of the patients had bilateral
involvement, and 23% had pleural effusions on admission,
which increased to 30% and 63%, respectively, during hospi-
talization (23). Despite some lung deterioration, which was
visible on chest x-ray, most patients improved clinically. In
this study, progressive lung deterioration within 48–72 hours
(noted in 41% of the patients) was not a significant risk factor
for ICU admission or death. Bilateral involvement on admis-
sion, on the other hand, was the most powerful prognostic fac-
tor associated with poor outcome in the multivariate analysis. 
Identification of patients with Legionnaires’ disease has
important implications for the choice of initial therapy. Studies
comparing the clinical manifestations of Legionella pneumo-
nia to other types of pneumonia have indicated that Legion-
naires’ disease is not “atypical” and that individual clinical
features such as diarrhea, confusion, hyponatremia, and chest
x-ray findings are not sufficiently distinctive to distinguish
Legionnaires’ disease from other types of community-
acquired pneumonia (18,24–26). The results of cultures
Figure 3. Survival curves and urinary antigen test results. A: Intensive care unit ICU)–free survival for patients with a positive or negative urinary
Legionella antigen test (Binax Now, Binax, Portland, ME):___ negative urinary antigen test (n=51); ----- positive urinary antigen test (n=86). B: ICU-
free survival for patients with a negative urinary Legionella antigen test (Binax Now):___ adequate antibiotic therapy started within 24 h after
admission (n=38); ----- adequate antibiotic therapy started more than 24 h after admission (n=13). C: ICU-free survival for patients with a positive
urinary Legionella antigen test (Binax Now): ___  adequate antibiotic therapy started within 24 h after admission (n=.46); ----- adequate antibiotic
therapy started >24 h after admission (n=40).Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1453
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require several days, and serum antibody tests have a low sen-
sitivity. In patients with Legionnaires’ disease related to this
outbreak, sensitivity was approximately 43% for one of the
three separate antibody tests and 61% for any of the tests,
using a positive culture result, a urinary antigen test with posi-
tive results, or both as the criterion standard (E. Yzerman,
pers. comm.). 
Detection of L. pneumophila antigens in a urine sample
provides a diagnosis within 1 hour, with a specificity of 95%
to 100% (11) (Binax Now Legionella urinary antigen test,
Binax). Patients in our study with a positive urine test during
hospitalization had an increased risk for ICU admission or
death, in accordance with data indicating that the percentage
of positive test results increased with the clinical severity of
the disease (27). Although the urinary antigen test was done
retrospectively in many patients (median 9 days after the first
symptoms, range 0–25 days), the number of positive urinary
tests is not lower during the first 3 days after symptoms than
after 3 weeks of illness (28). The urinary antigen test used dur-
ing this outbreak detects L. pneumophila serogroup 1, which is
responsible for approximately 70%–80% of Legionnaires’ dis-
ease cases in the United States and Europe.
Increased deaths associated with delay of adequate treat-
ment for Legionnaires’ disease has been reported earlier (1,5);
in patients suspected of having Legionnaires’ disease, ade-
quate therapy should therefore be started as soon as possible.
To ensure coverage of potential
L. pneumophila infections in every patient, the recommen-
dations for treatment of patients with community-acquired
pneumonia have been expanded. The new guidelines from the
Infectious Diseases Society of America recommend an
extended-spectrum cephalosporin plus a macrolide or a fluoro-
quinolone alone, for every hospitalized patient in whom no
pathogen is defined (6). This approach may lead to overtreat-
ment since 2%–13% of community-acquired pneumonia is
caused by L. pneumophila (18,29,30). Therefore, this approach
is costly and, in addition, may contribute to macrolide and flu-
oroquinolone resistance. 
The results of our study suggest that a more tailored
approach of patients with community-acquired pneumonia
may be possible. When Legionnaires’ disease is considered in
the differential diagnosis of patients with community-acquired
pneumonia, a urinary antigen test should be done on admis-
sion. If test results are positive, the patient should be treated
immediately with a fluoroquinolone or a macrolide since a
positive urinary test on admission identifies the patients with
Legionnaires’ disease caused by L. pneumophila serogroup 1
and a high risk for ICU admission or death. If the urinary anti-
gen test gives negative results, deferring anti-Legionella ther-
apy for the first 24 hours after admission, pending the
diagnostic work-up, may be justified because the outcome in
Legionnaires’ disease is not influenced. In this way, unneces-
sary use of antibiotics in patients hospitalized with commu-
nity- acquired pneumonia may be avoided.
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